Related Experiment Video
Updated: Nov 14, 2025
Whole-cell MALDI-TOF Mass Spectrometry is an Accurate and Rapid Method to Analyze Different Modes of Macrophage Activation
Published on: December 26, 2013
A fine line between macrophage activation syndrome and multisystem inflammatory syndrome in children - literature
Agnieszka Poniecka1, Elżbieta Smolewska2,1
1Department of Paediatric Cardiology and Rheumatology, Medical University of Lodz, Poland.
Insights
Multisystem inflammatory syndrome in children (MIS-C) is linked to COVID-19, presenting similar to Kawasaki disease. Early diagnosis and treatment are crucial for managing this serious condition in pediatric patients.
Area of Science:
- Pediatric Rheumatology
- Infectious Diseases
- Critical Care Medicine
Background:
- Multisystem inflammatory syndrome in children (MIS-C) is a serious condition associated with SARS-CoV-2 infection.
- Initial observations suggested mild COVID-19 in children, but MIS-C emerged as a severe complication.
- MIS-C shares clinical features with Kawasaki disease, toxic shock syndrome, and macrophage activation syndrome.
Purpose of the Study:
- To compare global reports of MIS-C with two recent pediatric cases.
- To highlight diagnostic challenges and symptom differentiation in MIS-C.
Main Methods:
- Comparative analysis of published MIS-C case reports.
- Detailed review of two hospitalized pediatric patients with complex symptoms requiring MIS-C differentiation.
Main Results:
- The article reviews worldwide MIS-C reports and presents two patient cases.
- Diagnostic workups for the presented cases involved differentiating numerous symptoms from MIS-C.
Conclusions:
- MIS-C is a significant pediatric concern linked to SARS-CoV-2.
- Timely and accurate diagnosis is essential for appropriate management of MIS-C.
- Further research is needed to fully understand MIS-C pathophysiology and optimize treatment strategies.
Abstract:
Multisystem inflammatory syndrome in children is a newly described condition temporarily associated with severe acute respiratory syndrome coronavirus 2. The primary observations indicated coronavirus disease 2019 infection in children to be mild. However, recent reports have revealed a correlation between multisystem inflammatory symptoms and coronavirus infection. The manifestation of the disease is similar to Kawasaki disease, toxic shock syndrome and macrophage activation syndrome. Treatment includes intravenous corticosteroids, immunoglobulin and biological therapy (anakinra, tocilizumab, infliximab). In this article we compare world reports of multisystem inflammatory syndrome in children to case reports of two patients who were hospitalized recently at the Department of Paediatric Cardiology and Rheumatology. In the course of diagnostics they presented numerous symptoms which required differentiation from multisystem inflammatory syndrome in children.
